Company Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States.
The company’s product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum.
It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts.
The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma.
Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jun 15, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Jayson Rieger |
Contact Details
Address: 44 West Gay Street, Suite 400 West Chester, Pennsylvania 19380 United States | |
| Phone | 484 453 3300 |
| Website | verrica.com |
Stock Details
| Ticker Symbol | VRCA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001660334 |
| CUSIP Number | 92511W207 |
| ISIN Number | US92511W2070 |
| Employer ID | 46-3137900 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jayson M. Rieger M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| John J. Kirby CPA | Interim Chief Financial Officer |
| David Zawitz | Chief Operating Officer |
| Eugene Scavola | Executive Vice President of Technical Operations |
| Dr. Bradley J. Catalone MBA, Ph.D. | Head of Drug Development |
| Dr. Noah L. Rosenberg M.D. | Chief Medical Officer |
| Chris Chapman | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 29, 2026 | SCHEDULE 13G/A | Filing |
| Dec 30, 2025 | SCHEDULE 13D/A | Filing |
| Dec 30, 2025 | 8-K | Current Report |
| Dec 23, 2025 | EFFECT | Notice of Effectiveness |
| Dec 23, 2025 | 424B3 | Prospectus |
| Dec 15, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 10, 2025 | D | Notice of Exempt Offering of Securities |
| Dec 3, 2025 | SCHEDULE 13G | Filing |
| Nov 28, 2025 | SCHEDULE 13D/A | Filing |